Angelika Amon’s journey from her native Vienna, Austria, to Cambridge, Massachusetts, has been marked by milestones attesting to her ambition. Amon nursed a bottomless curiosity about the natural world at an early age and became smitten with cell biology in high school when a teacher showed the class movies of plant cells parceling out chromosomes during division.

That adolescent infatuation portended Amon’s scientific research into the logic of the cell cycle—the perfectly timed succession of steps through which living cells replicate genetic material, split contents, and divide. Her efforts have revealed that the timely breakdown of proteins called cyclins helps ensure the cycle’s orderly progression.

“This work really showed how one stage of the cell cycle sets up the next,” says Amon.

Angelika Amon sitting at a microscope in her lab at Massachusetts Institute of Technology.

Amon arrived in the United States in 1994 to the Whitehead Institute for Biomedical Research in Cambridge, where she pursued a postdoctoral stint and earned a prestigious Whitehead fellowship for young scientists. She then struck out on her own, using genetic techniques to unravel the complex web of signals that orchestrate cell division in yeast.

Researching yeast led her to study a condition called aneuploidy—the presence of an abnormal number of chromosomes within a cell, which can lead to illnesses like Down syndrome. Amon is best known for her work on how aneuploidy throws vital cell functions into disarray—work that took shape at MIT’s Koch Institute for Integrative Cancer Research, where she was appointed a faculty member in 1999.

Angelika Amon sitting in an outdoor brick amphitheater.

Considered among the world’s leading geneticists and experts on cell division, Amon has broadened her arena into the biggest human scourge brought about by unchecked cell division: cancer. Recently, she and her colleagues found that aneuploid human cells trigger an innate immune response, which helps curb runaway cell division, hinting at a potential new therapeutic approach for the oncological world.

 

Awards and Accomplishments

  • Breakthrough Prize in Life Sciences (2019)
  • Vanderbilt Prize in Biomedical Sciences (2018)
  • American Academy of Arts and Sciences, Member (2017)
  • Elected Foreign Associate to EMBO (2015)
  • Elected Foreign Associate to the Austrian Academy of Sciences (2015)
  • Genetics Society of America Medal (2014)
  • Ernst Jung Prize for Medicine (2013)
  • National Academy of Sciences, Member (2010)
  • National Academy of Sciences Award in Molecular Biology (2008)
  • Paul Marks Prize (2007)
  • ASBMB Amgen Award (2007)
  • Alan T. Waterman Award (2003)
  • Eli Lilly and Company Research Award (2003)
  • Howard Hughes Medical Institute, HHMI Investigator (2000)

 

It is with sadness that we mourn the passing of Angelika Amon. “Angelika was a passionate leader in her field, she lived and taught with brightness and enthusiasm,” says Rick Kinsel, president of the Vilcek Foundation. “She will be sincerely missed.”

Amon passed away on October 29, 2020. She will be remembered as a dedicated scientist and mentor who was passionate about her research.

Tags
aneuploidy Austria biology biomedical science cancer research cell function cell growth chromosomes Howard Hughes Medical Institute MIT molecular biology

Jury Members

2019 Vilcek Prize in Biomedical Science

Titia de Lange

Leon Hess Professor and Head of the Laboratory of Cell Biology and Genetics, The Rockefeller University

Lily Jan

Jack and De Loris Lange Endowed Chair of Physiology and Biophysics, University of California San Francisco

Dan R. Littman

Helen L. and Martin S. Kimmel Professor of Molecular Immunology, New York University School of Medicine

Joan Massagué

Director, Memorial Sloan Kettering Cancer Center

Ruslan Medzhitov

Sterling Professor of Immunobiology, Yale School of Medicine

Huda Zoghbi

Professor of Molecular and Human Genetics, Baylor College of Medicine

Related Prize Recipients

Peter Walter

Peter Walter receives the Vilcek Prize in Biomedical Science for his fundamental insights into the process of protein translocation within cells, and for uncovering signaling mechanisms that cells deploy while facing stress.
Portrait of Peter Walter

Alexander Varshavsky

Alexander Varshavsky receives the Vilcek Prize in Biomedical Science for fundamental insights into the role of regulated protein degradation and the ubiquitin system in controlling protein levels within cells, with implications for an array of diseases, including cancer.
Alexander Varshavsky

Silvi Rouskin

Silvi Rouskin receives the Vilcek Prize for Creative Promise in Biomedical Science for developing methods to unravel the shapes of RNA molecules inside cells and aiding the potential development of RNA-based therapeutics.
Portrait of Silvi Rouskin

You may also be interested in

February 8, 2019

Mutations and Multiplication: Angelika Amon Unravels Cell Division

“We showed how the cell cycle is interconnected,” Angelika says, “and how one cell cycle phase sets up the next one.”
A photo of Angelika Amon
March 19, 2020

Kivanç Birsoy: “I feel like I contribute—at least—to the understanding of this disease”

Kivanç Birsoy’s research at The Rockefeller University focuses on cancer cell metabolism and its therapeutic applications.
Kivanc Birsoy is the head of Birsoy lab at Rockefeller University
February 22, 2022

Vishva M. Dixit: A scientist who swings for the fences

Vilcek Prizewinner Vishva M. Dixit’s career has been fueled by his passion for discovery, and his ambition to make a lasting impact on medicine.
Vishva Dixit with a big smile and a multicolor button-down.